Pfizer Streamlines Upper Management; Katen Positioned As Heir Apparent
Executive Summary
Pfizer's newly created corporate executive committee streamlines the company's top management structure
You may also be interested in...
Pfizer’s Shedlarz retires
Pfizer Vice Chairman David Shedlarz will retire at the end of the year, the company announces Oct. 25. Shedlarz was considered a potential successor to then-CEO Hank McKinnell when he was promoted to vice chairman, along with Karen Katen and current CEO Jeffrey Kindler in 2006 (1"The Pink Sheet" Feb. 28, 2005, p. 20). Shedlarz is noted for leading the integration of the Pharmacia acquisition in 2003, which has been a challenge for Pfizer (2"The Pink Sheet" July 22, 2002, p. 3). Shedlarz joined the company in 1976; he served 10 years as CFO, and most recently led strategic planning and business development...
Pfizer’s Shedlarz retires
Pfizer Vice Chairman David Shedlarz will retire at the end of the year, the company announces Oct. 25. Shedlarz was considered a potential successor to then-CEO Hank McKinnell when he was promoted to vice chairman, along with Karen Katen and current CEO Jeffrey Kindler in 2006 (1"The Pink Sheet" Feb. 28, 2005, p. 20). Shedlarz is noted for leading the integration of the Pharmacia acquisition in 2003, which has been a challenge for Pfizer (2"The Pink Sheet" July 22, 2002, p. 3). Shedlarz joined the company in 1976; he served 10 years as CFO, and most recently led strategic planning and business development...
McKindler? New Pfizer CEO Echoes McKinnell’s Views On Payers, Scale
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said